Pfizer and SFJ Pharmaceuticals Group have entered into a collaborative development agreement to conduct a Phase III trial for Pfizer’s investigational pan-human epidermal growth factor receptor inhibitor, dacomitinib. The trial will evaluate dacomitinib as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor (EGFR).   SFJ will provide the funding and clinical development supervision to sup...